Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Akebia Therapeutics stock | 2.6

Own Akebia Therapeutics stock in just a few minutes.

Posted

Fact checked

Akebia Therapeutics, Inc is a biotechnology business based in the US. Akebia Therapeutics shares (AKBA) are listed on the NASDAQ and all prices are listed in US Dollars. Akebia Therapeutics employs 358 staff and has a trailing 12-month revenue of around USD$340.2 million.

How to buy shares in Akebia Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Akebia Therapeutics. Find the stock by name or ticker symbol: AKBA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Akebia Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$2.6, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Akebia Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Akebia Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Akebia Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Akebia Therapeutics's share price has had significant negative movement.

Its last market close was USD$2.6, which is 74.38% down on its pre-crash value of USD$10.15 and 46.35% down on the lowest point reached during the March crash when the shares fell as low as USD$3.805.

If you had bought USD$1,000 worth of Akebia Therapeutics shares at the start of February 2020, those shares would have been worth USD$791.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$330.15.

Akebia Therapeutics share price

Use our graph to track the performance of AKBA stocks over time.

Akebia Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$2.6
52-week range USD$2.34 - USD$13.71
50-day moving average USD$3.4543
200-day moving average USD$9.0134
Wall St. target price USD$6.86
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.395

Buy Akebia Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Akebia Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akebia Therapeutics price performance over time

Historical closes compared with the close of $2.6 from 2020-11-16

1 week (2020-11-23) -15.31%
1 month (2020-10-30) 17.12%
3 months (2020-08-28) -74.71%
6 months (2020-05-29) -77.66%
1 year (2019-11-29) -58.66%
2 years (2018-11-30) -67.82%
3 years (2017-11-30) -83.29%
5 years (2015-11-30) -75.77%

Akebia Therapeutics financials

Revenue TTM USD$340.2 million
Gross profit TTM USD$26.5 million
Return on assets TTM -14.83%
Return on equity TTM -86.68%
Profit margin -113.35%
Book value $2.587
Market capitalisation USD$530.3 million

TTM: trailing 12 months

Shorting Akebia Therapeutics shares

There are currently 22.2 million Akebia Therapeutics shares held short by investors – that's known as Akebia Therapeutics's "short interest". This figure is 141.8% up from 9.2 million last month.

There are a few different ways that this level of interest in shorting Akebia Therapeutics shares can be evaluated.

Akebia Therapeutics's "short interest ratio" (SIR)

Akebia Therapeutics's "short interest ratio" (SIR) is the quantity of Akebia Therapeutics shares currently shorted divided by the average quantity of Akebia Therapeutics shares traded daily (recently around 12.0 million). Akebia Therapeutics's SIR currently stands at 1.85. In other words for every 100,000 Akebia Therapeutics shares traded daily on the market, roughly 1850 shares are currently held short.

However Akebia Therapeutics's short interest can also be evaluated against the total number of Akebia Therapeutics shares, or, against the total number of tradable Akebia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akebia Therapeutics's short interest could be expressed as 0.15% of the outstanding shares (for every 100,000 Akebia Therapeutics shares in existence, roughly 150 shares are currently held short) or 0.1781% of the tradable shares (for every 100,000 tradable Akebia Therapeutics shares, roughly 178 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Akebia Therapeutics.

Find out more about how you can short Akebia Therapeutics stock.

Akebia Therapeutics share dividends

We're not expecting Akebia Therapeutics to pay a dividend over the next 12 months.

Akebia Therapeutics share price volatility

Over the last 12 months, Akebia Therapeutics's shares have ranged in value from as little as $2.34 up to $13.71. A popular way to gauge a stock's volatility is its "beta".

AKBA.US volatility(beta: 1.65)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Akebia Therapeutics's is 1.6459. This would suggest that Akebia Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Akebia Therapeutics overview

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of renal therapeutics for patients with kidney diseases. The company's lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of HIF-prolyl hydroxylases-targeted compounds worldwide. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site